0001104659-22-107708.txt : 20221011 0001104659-22-107708.hdr.sgml : 20221011 20221011160532 ACCESSION NUMBER: 0001104659-22-107708 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20221007 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221011 DATE AS OF CHANGE: 20221011 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monterey Bio Acquisition Corp CENTRAL INDEX KEY: 0001860663 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 852204842 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40861 FILM NUMBER: 221304102 BUSINESS ADDRESS: STREET 1: 17 STATE STREET STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10004 BUSINESS PHONE: 917-267-0216 MAIL ADDRESS: STREET 1: 17 STATE STREET STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10004 8-K 1 tm2228010d1_8k.htm FORM 8-K
0001860663 false 0001860663 2022-10-07 2022-10-07 0001860663 MTRY:UnitsMember 2022-10-07 2022-10-07 0001860663 us-gaap:CommonStockMember 2022-10-07 2022-10-07 0001860663 MTRY:RedeemableWarrantsMember 2022-10-07 2022-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 7, 2022

 

Monterey Bio Acquisition Corporation
(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction
of incorporation)		 001-40861
(Commission
File Number)		 85-2204842
(I.R.S. Employer
Identification No.)

 

17 State Street

21st Floor

New York, NY

(Address of principal executive offices)

10004

(Zip Code)

 

(917) 267-0216
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name or former address, if changed since last report)  

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Units, each consisting of one share of Common Stock and one redeemable Warrant   MTRYU   The Nasdaq Stock Market LLC
         
Common Stock, par value $0.0001 per share   MTRY   The Nasdaq Stock Market LLC
         
Redeemable Warrants, each Warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share   MTYRW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

The information provided in Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

 

On October 7, 2022, Monterey Bio Acquisition Corporation (the “Company”) issued an unsecured promissory note to each of (i) NorthStar Bio Ventures, LLC (“NorthStar”) in the amount of up to $525,000 (the “NorthStar Note”) and (ii) Chardan Monterey Investments, LLC (“Chardan Monterey” and together with NorthStar, the “Co-Sponsors”) in the amount of up to $175,000 (the “Chardan Monterey Note” and together with the NorthStar Note, the “Notes”). The terms of the Notes are identical other than the principal amounts. The proceeds of the Notes, may be drawn down from time to time prior to the Maturity Date (as defined below) upon request by the Company.

 

The Notes bear no interest and each principal balance is payable on the date of the consummation of the Company’s initial business combination (the “Maturity Date”). On or before the Maturity Date, each Co-Sponsor has the option to convert all or any portion of the principal outstanding under its Note into warrants (“Working Capital Warrants”) at a conversion price of $1.00 per warrant. The terms of the Working Capital Warrants, if any, would be identical to the terms of the private placement warrants issued by the Company at the time of its initial public offering (the “IPO”), as described in the prospectus for the IPO dated September 30, 2021 and filed with the U.S. Securities and Exchange Commission, including the transfer restrictions applicable thereto. Each Note is subject to customary events of default, the occurrence of certain of which automatically triggers the unpaid principal balance of such Note and all other sums payable with regard to such Note becoming immediately due and payable.

 

The issuance of the each Note was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.

 

The foregoing description of the Notes is qualified in its entirety by reference to the full text of the Notes, copies of which are filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
10.1   Promissory Note, dated October 7, 2022, issued by Monterey Bio Acquisition Corporation to   NorthStar Bio Ventures, LLC
10.2   Promissory Note, dated October 7, 2022, issued by Monterey Bio Acquisition Corporation to Chardan Monterey Investments, LLC
104   Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Monterey Bio Acquisition CorpORaTION
   
   
  By: /s/ Sanjeev Satyal 
    Name: Sanjeev Satyal
    Title: Chief Executive Officer

 

Date: October 11, 2022

 

 

 EX-10.1 2 tm2228010d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”).  THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF MAKER REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

PROMISSORY NOTE

 

Principal Amount:  $525,000 Dated as of October 7, 2022

 

Monterey Bio Acquisition Corporation, a Delaware corporation (the “Maker”), promises to pay to the order of NorthStar Bio Ventures, LLC, a Delaware limited liability company, or its registered assigns or successors in interest (the “Payee”), or order, the principal sum of Five Hundred Twenty Five Thousand Dollars ($525,000), or such lesser amount as shall have been advanced by Payee to Maker and shall remain unpaid under this Note, in lawful money of the United States of America, on the terms and conditions described below.  All payments on this Note shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

 

1.            Principal. The principal balance of Note shall be payable on the date on which Maker consummates its initial business combination (the “Maturity Date”). The principal balance may be prepaid at any time. Under no circumstances shall any individual, including but not limited to any officer, director, employee or shareholder of the Maker, be obligated personally for any obligations or liabilities of the Maker hereunder.

 

2.            Interest. No interest shall accrue on the unpaid principal balance of this Note.

 

3.            Drawdown Requests. The principal of this Note may be drawn down from time to time prior to the Maturity Date, upon request from Maker to Payee (each, a “Drawdown Request”). Payee shall fund each Drawdown Request within two (2) business days after receipt of a Drawdown Request; provided, however, that the maximum amount of drawdowns collectively under this Note is Five Hundred Twenty Five Thousand Dollars ($525,000). Once an amount is drawn down under this Note, it shall not be available for future Drawdown Requests even if prepaid. No fees, payments or other amounts shall be due to Payee in connection with, or as a result of, any Drawdown Request by Maker.

 

4.            Application of Payments. All payments shall be applied first to payment in full of any costs incurred in the collection of any sum due under this Note, including (without limitation) reasonable attorney’s fees, then to the payment in full of any late charges and finally to the reduction of the unpaid principal balance of this Note.

 

5.            Conversion.

 

(a)            Optional Conversion. On or before the Maturity Date, at the option of Payee, any amounts outstanding under this Note may be converted into warrants (“Warrants”) at a conversion price of $1.00 per Warrant (the “Warrant Conversion Price”). Each Warrant will contain terms identical to those of the warrants Maker issued in a private placement (the “Private Placement”) simultaneously with the closing of Maker’s initial public offering (the “IPO”) entitling the holder thereof to purchase one share of Class common stock, par value $0.0001, of Maker (each, a “Share”) at an exercise price of $11.50 per Share as more fully described in the prospectus for the IPO dated September 30, 2021 and filed with the Securities and Exchange Commission (the “SEC”). Before this Note may be converted under this Section 5(a), Payee shall surrender this Note, duly endorsed, at the office of Maker and shall state therein the amount of the unpaid principal of this Note to be converted and the name or names in which the certificates for Warrants are to be issued. The conversion shall be deemed to have been made immediately prior to the close of business on the date of the surrender of this Note and the person or persons entitled to receive the Warrants upon such conversion shall be treated for all purposes as the record holder or holders of such Warrants as of such date. For the avoidance of doubt, in the event that all principal on this Note has been paid in full on or prior to the Maturity Date, then Payee shall not be entitled to convert any portion of this Note into Warrants.

 

 

 

 

(b)           Remaining Principal. All accrued and unpaid principal of this Note that is not then converted into Warrants shall continue to remain outstanding and to be subject to the terms and conditions of this Note.

 

(c)            Fractional Warrants; Effect of Conversion. No fractional warrants shall be issued upon conversion of this Note. In lieu of issuing any fractional warrants to Payee upon the conversion of this Note, Maker shall pay to Payee an amount in cash equal to the product obtained by multiplying the Warrant Conversion Price by the fraction of a warrant not issued pursuant to the previous sentence. Upon conversion of this Note in full and the payment of any amounts specified in this Section 5(c), this Note shall be cancelled and void without further action of Maker or Payee, and Maker shall be forever released from all its obligations and liabilities under this Note.

 

6.            Events of Default. The following shall constitute an event of default (“Event of Default”):

 

(a)            Failure to Make Required Payments. Failure by Maker to pay the principal amount due pursuant to this Note within five (5) business days of the date specified in Section 1 above.

 

(b)           Voluntary Bankruptcy, Etc. The commencement by Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of Maker generally to pay its debts as such debts become due, or the taking of corporate action by Maker in furtherance of any of the foregoing.

 

(c)            Involuntary Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of Maker in an involuntary case under any applicable bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days.

 

7.            Remedies.

 

(a)            Upon the occurrence of an Event of Default specified in Section 6(a) hereof, Payee may, by written notice to Maker, declare this Note to be due immediately and payable, whereupon the unpaid principal amount of this Note, and all other amounts payable thereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding.

 

(b)            Upon the occurrence of an Event of Default specified in Sections 6(b) or 6(c), the unpaid principal balance of this Note, and all other sums payable with regard to this Note, shall automatically and immediately become due and payable, in all cases without any action on the part of Payee.

 

8.            Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment; and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, on any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.

 

9.            Unconditional Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to Maker or affecting Maker’s liability hereunder.

 

2 

 

 

10.         Notices. All notices, statements or other documents which are required or contemplated by this Agreement shall be in writing and delivered (i) personally or sent by first class registered or certified mail, overnight courier service to the address designated in writing by such party, (ii) by facsimile to the number most recently provided to such party or such other address or fax number as may be designated in writing by such party or (iii) by electronic mail, to the electronic mail address most recently provided to such party or such other electronic mail address as may be designated in writing by such party.  Any notice or other communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt of written confirmation, if sent by facsimile or electronic mail, one (1) business day after delivery to an overnight courier service or five (5) days after mailing if sent by mail.

 

11.         Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

 

12.         Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

13.         Trust Waiver.  Notwithstanding anything herein to the contrary, the Payee hereby waives any and all right, title, interest or claim of any kind (“Claim”) in or to any distribution of or from the trust account in which a portion of the proceeds of the IPO and the Private Placement were deposited, as described in greater detail in the registration statement and prospectus filed with the SEC in connection with the IPO, and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the trust account for any reason whatsoever.

 

14.         Amendment; Waiver.  Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Maker and the Payee.

 

15.         Assignment.  No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent of the other party hereto and any attempted assignment without the required consent shall be void.

 

[Signature Page Follows]

 

3 

 

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first above written.

 

  MONTEREY BIO ACQUISITION CORPORATION
   
   
  By: /s/ William McKeever
  Name: William McKeever
  Title: Chief Financial Officer

 

4 

 

 EX-10.2 3 tm2228010d1_ex10-2.htm EXHIBIT 10.2

Exhibit 10.2

 

THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”).  THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF MAKER REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

PROMISSORY NOTE

 

Principal Amount:  $175,000 Dated as of October 7, 2022

 

Monterey Bio Acquisition Corporation, a Delaware corporation (the “Maker”), promises to pay to the order of Chardan Monterey Investments LLC, a Delaware limited liability company, or its registered assigns or successors in interest (the “Payee”), or order, the principal sum of One Hundred Seventy Five Thousand Dollars ($175,000), or such lesser amount as shall have been advanced by Payee to Maker and shall remain unpaid under this Note, in lawful money of the United States of America, on the terms and conditions described below.  All payments on this Note shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

  

1.            Principal. The principal balance of Note shall be payable on the date on which Maker consummates its initial business combination (the “Maturity Date”). The principal balance may be prepaid at any time. Under no circumstances shall any individual, including but not limited to any officer, director, employee or shareholder of the Maker, be obligated personally for any obligations or liabilities of the Maker hereunder.

 

2.            Interest. No interest shall accrue on the unpaid principal balance of this Note.

 

3.            Drawdown Requests. The principal of this Note may be drawn down from time to time prior to the Maturity Date, upon request from Maker to Payee (each, a “Drawdown Request”). Payee shall fund each Drawdown Request within two (2) business days after receipt of a Drawdown Request; provided, however, that the maximum amount of drawdowns collectively under this Note is One Hundred Seventy Five Thousand Dollars ($175,000). Once an amount is drawn down under this Note, it shall not be available for future Drawdown Requests even if prepaid. No fees, payments or other amounts shall be due to Payee in connection with, or as a result of, any Drawdown Request by Maker.

 

4.            Application of Payments. All payments shall be applied first to payment in full of any costs incurred in the collection of any sum due under this Note, including (without limitation) reasonable attorney’s fees, then to the payment in full of any late charges and finally to the reduction of the unpaid principal balance of this Note.

 

5.            Conversion.

 

(a)            Optional Conversion. On or before the Maturity Date, at the option of Payee, any amounts outstanding under this Note may be converted into warrants (“Warrants”) at a conversion price of $1.00 per Warrant (the “Warrant Conversion Price”). Each Warrant will contain terms identical to those of the warrants Maker issued in a private placement (the “Private Placement”) simultaneously with the closing of Maker’s initial public offering (the “IPO”) entitling the holder thereof to purchase one share of Class common stock, par value $0.0001, of Maker (each, a “Share”) at an exercise price of $11.50 per Share as more fully described in the prospectus for the IPO dated September 30, 2021 and filed with the Securities and Exchange Commission (the “SEC”). Before this Note may be converted under this Section 5(a), Payee shall surrender this Note, duly endorsed, at the office of Maker and shall state therein the amount of the unpaid principal of this Note to be converted and the name or names in which the certificates for Warrants are to be issued. The conversion shall be deemed to have been made immediately prior to the close of business on the date of the surrender of this Note and the person or persons entitled to receive the Warrants upon such conversion shall be treated for all purposes as the record holder or holders of such Warrants as of such date. For the avoidance of doubt, in the event that all principal on this Note has been paid in full on or prior to the Maturity Date, then Payee shall not be entitled to convert any portion of this Note into Warrants.

 

 

 

(b)            Remaining Principal. All accrued and unpaid principal of this Note that is not then converted into Warrants shall continue to remain outstanding and to be subject to the terms and conditions of this Note.

 

(c)            Fractional Warrants; Effect of Conversion. No fractional warrants shall be issued upon conversion of this Note. In lieu of issuing any fractional warrants to Payee upon the conversion of this Note, Maker shall pay to Payee an amount in cash equal to the product obtained by multiplying the Warrant Conversion Price by the fraction of a warrant not issued pursuant to the previous sentence. Upon conversion of this Note in full and the payment of any amounts specified in this Section 5(c), this Note shall be cancelled and void without further action of Maker or Payee, and Maker shall be forever released from all its obligations and liabilities under this Note.

 

6.            Events of Default. The following shall constitute an event of default (“Event of Default”):

 

(a)            Failure to Make Required Payments. Failure by Maker to pay the principal amount due pursuant to this Note within five (5) business days of the date specified in Section 1 above.

 

(b)            Voluntary Bankruptcy, Etc. The commencement by Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of Maker generally to pay its debts as such debts become due, or the taking of corporate action by Maker in furtherance of any of the foregoing.

 

(c)            Involuntary Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of Maker in an involuntary case under any applicable bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days.

 

7.            Remedies.

 

(a)            Upon the occurrence of an Event of Default specified in Section 6(a) hereof, Payee may, by written notice to Maker, declare this Note to be due immediately and payable, whereupon the unpaid principal amount of this Note, and all other amounts payable thereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding.

 

(b)            Upon the occurrence of an Event of Default specified in Sections 6(b) or 6(c), the unpaid principal balance of this Note, and all other sums payable with regard to this Note, shall automatically and immediately become due and payable, in all cases without any action on the part of Payee.

 

8.            Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment; and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, on any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.

 

9.            Unconditional Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to Maker or affecting Maker’s liability hereunder.

 

2 

 

 

10.         Notices. All notices, statements or other documents which are required or contemplated by this Agreement shall be in writing and delivered (i) personally or sent by first class registered or certified mail, overnight courier service to the address designated in writing by such party, (ii) by facsimile to the number most recently provided to such party or such other address or fax number as may be designated in writing by such party or (iii) by electronic mail, to the electronic mail address most recently provided to such party or such other electronic mail address as may be designated in writing by such party.  Any notice or other communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt of written confirmation, if sent by facsimile or electronic mail, one (1) business day after delivery to an overnight courier service or five (5) days after mailing if sent by mail.

 

11.         Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

 

12.         Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

13.         Trust Waiver.  Notwithstanding anything herein to the contrary, the Payee hereby waives any and all right, title, interest or claim of any kind (“Claim”) in or to any distribution of or from the trust account in which a portion of the proceeds of the IPO and the Private Placement were deposited, as described in greater detail in the registration statement and prospectus filed with the SEC in connection with the IPO, and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the trust account for any reason whatsoever.

 

14.         Amendment; Waiver.  Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Maker and the Payee.

 

15.         Assignment.  No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent of the other party hereto and any attempted assignment without the required consent shall be void.

 

[Signature Page Follows]

 

3 

 

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first above written.

 

  MONTEREY BIO ACQUISITION CORPORATION
   
   
  By: /s/ William McKeever 
  Name: William McKeever
  Title:    Chief Financial Officer

 

4 

 

 EX-101.SCH 4 mtry-20221007.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 mtry-20221007_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 mtry-20221007_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Units [Member] Common Stock [Member] Redeemable Warrants [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 mtry-20221007_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Oct. 07, 2022
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 07, 2022
Entity File Number 001-40861
Entity Registrant Name Monterey Bio Acquisition Corporation
Entity Central Index Key 0001860663
Entity Tax Identification Number 85-2204842
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 17 State Street
Entity Address, Address Line Two 21st Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10004
City Area Code 917
Local Phone Number 267-0216
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units [Member]  
Title of 12(b) Security Units, each consisting of one share of Common Stock and one redeemable Warrant
Trading Symbol MTRYU
Security Exchange Name NASDAQ
Common Stock [Member]  
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol MTRY
Security Exchange Name NASDAQ
Redeemable Warrants [Member]  
Title of 12(b) Security Redeemable Warrants, each Warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share
Trading Symbol MTYRW
Security Exchange Name NASDAQ
XML 9 tm2228010d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001860663 2022-10-07 2022-10-07 0001860663 MTRY:UnitsMember 2022-10-07 2022-10-07 0001860663 us-gaap:CommonStockMember 2022-10-07 2022-10-07 0001860663 MTRY:RedeemableWarrantsMember 2022-10-07 2022-10-07 iso4217:USD shares iso4217:USD shares 0001860663 false 8-K 2022-10-07 Monterey Bio Acquisition Corporation DE 001-40861 85-2204842 17 State Street 21st Floor New York NY 10004 917 267-0216 false false false false Units, each consisting of one share of Common Stock and one redeemable Warrant MTRYU NASDAQ Common Stock, par value $0.0001 per share MTRY NASDAQ Redeemable Warrants, each Warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share MTYRW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 4 24 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://montereybio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2228010d1_8k.htm mtry-20221007.xsd mtry-20221007_def.xml mtry-20221007_lab.xml mtry-20221007_pre.xml tm2228010d1_ex10-1.htm tm2228010d1_ex10-2.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2228010d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "mtry-20221007_def.xml" ] }, "inline": { "local": [ "tm2228010d1_8k.htm" ] }, "labelLink": { "local": [ "mtry-20221007_lab.xml" ] }, "presentationLink": { "local": [ "mtry-20221007_pre.xml" ] }, "schema": { "local": [ "mtry-20221007.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 2, "memberStandard": 1, "nsprefix": "MTRY", "nsuri": "http://montereybio.com/20221007", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm2228010d1_8k.htm", "contextRef": "From2022-10-07to2022-10-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://montereybio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "tm2228010d1_8k.htm", "contextRef": "From2022-10-07to2022-10-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "MTRY_RedeemableWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Warrants [Member]" } } }, "localname": "RedeemableWarrantsMember", "nsuri": "http://montereybio.com/20221007", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "domainItemType" }, "MTRY_UnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Units [Member]" } } }, "localname": "UnitsMember", "nsuri": "http://montereybio.com/20221007", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://montereybio.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001104659-22-107708-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-107708-xbrl.zip M4$L#!!0 ( *Z 2U4U)&_[Q0, (L. 1 ;71R>2TR,#(R,3 P-RYX M2]..E(]L+4;$E(LD! M^NOO2K;Y- 1H>WF2=\\YVI56*]%\/4T3\@A2,<%;3E#S'0(\$C'CPY9SVW?? M]"_;;8>\?O7/WP1_S7]=EUPS2.(&N1*1V^8#\9)\H"DTR#O@(*D6\B6YHTEF M+.*:)2#)I4C'"6A 1SY3@YS6@C-*7'E-3FI"#KVZ[P?>EVZG;W%.#FQ,$\9'5?#@XN+"L]X2NH&< MAC(II4\\XPZI@KDR>MD./.-*4QZMX&,])RR#3[W/70@OAX\/"^AF7*'E([G\ %5H94M'!;N^H%[$I04)?4F'(W54%?/QJ J M";FK@A9KN49;64ET>\9MF+YAUN?,[DWOZYR4"JY!PBQDPA2Y@=<#WW^!1S6! M%+B^%C*]@@'-$LSH(:,)&S"(':*I'((V5:O&-(*G!1#(X2R5BJ& >/,SE<< MQ8"XYN!E)CT<6DK36PTX:I@Y:CF&F43F&[ES!H.:F6,[?^86@U+I(08 MZ1W'U*[\^FH4$Y<25$8;*AMM!$7$&*1F6.=+O2(/G6E#_[0T#3'S*(=XOR/E MA(:'IHP42/Y@KAVC_UN3Q$HZ-,G5XOM#F5[-)UE.MV@)WJ(G%-_K?:.)B0NI M"=_H0;ONE/PV[(C(2NV@F"^WY+G&Y 9U;,"UJ8H7D1X2Q&(9#@NBY!T1Q-:; MK2H"M9U@AFX^W'?JG;?DSNDKF1XD6I46=Z%U3#B;=^HOQ&/%C@CHZ>MZ6U!/ M,>VW.JI$(I%Q[!TVPSV+9)E2?MCE.'AGUM]'^VU*R_>E_1"I]ZOV.&!5)<_.I] M1S0R>_@EH5AX8[Y:4ZRP/I!4?.J=' U_1I[O-SCO=\Q"+K[=3';G72JUEJ?] M_N/CXQ'C#^B1BWMY%/!5LQ-.%5*1W)UML!FD_Y+B'RAA]Z?FQPQ)[&F]F#S= M2'+6,_6FU3X>'W&QZ(\&@V'_/U\^3X,E7B&?,*-;@'M9*7,66[GA^_?O^_'1 M#%I";F:"9G4<]S,ZNS/KHZ':%QC N\/J\&%?GAU++ MRCAMDWB.(JJ>W2BSXD7.>C=AQ/1UG_6O!=YXH_2M!X<96 MH>>;&U&DZ2B]F2!3)AD7RH," 6IZ82[*RLDLY#F2LSCN2/H+A-9:P]&PCZF2 MV1[3+0[]P3#M=W]*=]^9FR V9'38>*(W958-13-,X\KO4K -VV\#]ULT>VI8 M%;Q3W#[G)^_/1<8^;3@-K\ZDM9X&IC%LU 6-:],M'B_,1L9L+OBJ5M!4/%X9 M05YA3:3G<1%BH<=Q@RD24LK%WE1 M\ZPWV#JSBAX 1D&Q6CQ[6W?R1#^E-VS(%AOV1?THCQWJS !UYK7,(4-&@RX[ MTT'\I4[)[Y__;WSW;M3@ZR+CCYQI7SAN^W-[\>?=-2R:_I /#D@,&DD.\ M@N[%D2F@:47+YC!1L#-ZZ]Z(K_2(*@X&%#X+?!]Z9[MP6^% )6.P&WJN%4!K MOL$AUBF]OG?]0$(@5M.T(?B=[2IKA;20Z#R5TV]K_59[4HKR%YQ-W)VXA=/S"U$87T?9'[:3-YSS6AT)"ZI&AA MU[< :;7 9::O.H8\4.%/6 :"K%5NS P(G4-V0^]]PF 7[;[?N,$+(I6(G\KN M@JKN2*Q%6FU$/7.P*W?OR#EC$:(W>,U%C1%Y9"?T+Q&&9'_G7O9_1T@H+.BV MB?)[X$Z(;^,,Z7_R!@,8/;J2L5Q-#-A'=\(!*VG(@I_=6S!=8DK-2U7$&ET% M97PG; !H0T;\\K9&7#R8 80.K[D7NR*=LZ/(''+DG^X=N<:"\%#')1IXL0?N MA LVSI#^[]]*_PL6-E4_A79(^SSCJO9\C@2HD"OLA>"T*VVH)(TZ('#W/B" M*:*V9M;?UPAXQJQA^ZA6:VXE"VKM,"%.B&6/2I@RDQNK]"XB.Z"YA3"HN\-$ M."$WUB$(1"5MX3*@AVPIYX_:)+#W#CA>AZ& DN9_F=B&U998X%WP!"(-?@BS6&> M##$<'6;#J),VC*IM<)@G0PR/#[/AN),V'%?;X#!;+C B>Y882,.^N$\G<[:2S*,:'(U),CN MZ)\G#.KN/)U.R5USJ1#]+UG7C5QM^.YX4*8-.N$PNTY;AGGL DWM*D!:K7>9 M*2BQPQ3:W(?.!49P\\XCVBWP/E%07X?Y\&=NW@XM.:M\_KR/:K7.5K*@UB[3 M6K,\4H)=Q>YPJ]4MLH1D??8"DV?(^D,0I3F9-0,12Y\Z 6\1K=!6RPTS!J5W MF)I..26!5HDMONA8!$'4KGL9UVK1 ;J@X@ZST&N!35O .A&()]Z9]=;B:CZ' M>FX8WVH':FB#3CA,1_(@TAWG=CB:W9J/ M"@"]TAZJU=I;R8):.TQ'O_);@#F1!=AJQ2&^H.@.,\\",[O< M!4BKA2XS!25VF'EF%]S%)E@BML#P;!$;LM6"@X1!W1UFI$\=W:)1W[WH4M^] M:-!W.\Q(,V+)8@%]#5[-*%D@>*5B18%.. #QALQXYW)%;KR&S'QW3ZQB9I=Z MPVZ#%=IJ V#&H/0NE^I&(5$X3$A>$H98H).^76# TX2Z4NTVI EYT!OG[UU_ M8$K_8/R133&2G.$P23ZJWG@ 15KM2CUST!+G;V*__N9LD'6JLDU =D#],E]0=.?SG*E$"=T%&^RD(0]L ;V6![MOL02!F3N<_35%YJ\[A6JT_0!=4W'FV?!W- M* DN*4>5>4$.U@&]]]F"16I^._K:,:5#SDJRG7 JEKZH$-O\$DM^;24$(M!56[S5?AT6!6A;+D7_T-\+4%=_KX^E^\T/\T>! M])[_ 5!+ P04 " "N@$M5C+QZ2>L+ CD@ %0 &UT[$F^R.X]@[GG5LUU*2 M;C.=#$1!,L<4X 4I6_KW!< /D0 .27M3 +E(%.(]X OB$0!2Y.&;7[;K!#T2 MGL:,OAV,#PX'B-"(+6*Z>COX.!V>3$\O+@8HS3!=X(11\G9 V>"7G__Z%R3^ MO/EN.$3G,4D6Q^@]BX87=,E^0E=X38[1KX02CC/&?T*?<+*16]AYG!".3MGZ M(2$9$07YCH_1/P_&/V T'/:H]Q.A"\8_WEY4]=YEV4-Z/!H]/3T=4/:(GQB_ M3P\BMNY7X33#V2:M:CO<'A9_\O W24SOC^5?#@>_?O#Y32Z(VL\C*D\;A$9E%&R%EO<^/7KUR-56DH-Y7;.DW(? M1Z/23E6S*(U;]#4G:7R<*GN7+,*9ZO;.W2!0(?\W+&5#N6DXG@R/Q@?;=#$H M#[XZ@IPEY)8LD6KF<;9[$"BEL21A4&R[XV1I-Y-P/I+Q(TI6.",+N:/7-^HJ@D:NS=X0'K/%&7V9:SW:DWWQW>'9GVA M/=YY$V8LP\F+S-Z%OE_L9V9EI]]>.W'-9$; M+\6GAD6RS<0$1A:E25E%RPBL]J FAJ+NJG86->I-Y&C.N-EV.3.J.IPA&R;YH<_#EYRM>]DHCASK M(?Z:S*OZ\T,M+ -:<@X2=F&1^19/5UO3=^C6CA<)R)"+ML('7Z<#GY6,L26 M2 G1%RG][YO1ONJ7$+7.^$YB,AD?'OZH(/DPN_W]ZT<:9^D'LIX3KKDWBUT@ M )F2/:Z7>>]@P)#>GTJ!ON2:/]V1WVAH$&OY-:.*,&OWM^A<#@6@S?H08(B\ MD]'ES/C**UWYA?]&I !?^5NR(.(L8IZ0SYAS3-N^_[#6V6#09;<:&2"A=QCZ MN-.!V,M1J0]M!*FFM9FTV37W%2(ORXB&0>O:02F\@])J2R>D$J$O2A8<%F(% M32[$Q\[%9DWH!0_#J!612A4>)KJU%E2D%"GMM^4E)='!BCV.%B16J/SQ#_EQ MF']4?(C_?GW/HHWB6M2J-69J@E;OJ9JNMLI\;A4%TM,V1WM.5!DF1SZY^3]*(QP_RJG1;6QHRYQUO M,6GT?TT3%@:F,9B&FM;C(']+5G&:.4 M1-,%Q0I@#CY5J?3^:9G>D221M[I@VCVPV,2NB8$-Z\R8RJ"H >V!W*@(5(2$ MA<[9HURUBZ53SP;7]#X!,FRW,52)@\5(=]B3)!6&9)Q'FFIWVG1P9"A=$P18 MU=G19$%18_<&\I++D=*' D$ 4(2--9%QY"[1N.\SB- M<)+[.1?;])]C.K2N(0'MZJ 8PJ!@@=R!P.0!)3GD0/ "F= YR&9(ZE N]]7[YJP+-Y/,[ M8)-TF5L*[":;)#0U =%@-080L=>JQZF\47$J1BF.DPNZ(-O?R YLFZ%SRP5@ MLPF&)@J(#+LS (U"C)0:";DW.&YXO,9\-XVCCFG#%+K% S+:Y$-7!00(8 T@ MI%"CZ<6I[UEEAK<7"P%LO(SSQR([2 'U;H'IL-WD!A 'A$^[0X B$82:4;YA MNJ 1XP^L=KO$*=N(P7!WRA;PBJ4CRBU8O9K0Q*LU)"#(^O@$4&N$OLKO:4%, M/M*N*D"R!F_4G2P6XF"EQ3^7,25C\!A8M6X):[';Y,HB#(@FV!W 4*%\57Y M,@9=TY# F3RCN1/_X$SZ@C,)&IS)2\"9/;& P#EZ1G./_(-SU!>UEXR!C>NH"1 7)](T-\HZ(66]?\ MAK/'F$;P,AJ2>X$&,&TE1].&AX_=8!=#U2*YC/,-4K%8[_RRE#(_HTW3I'VH MR37A@=(TUCG(Y&K?6-RP-,/)?^*'UI-TN]@+(E;#5E :RO!PL=GK@B:/02+( MUTEW@:W\ <3ZN)I6[NQ7:INMZJ?I>F$0(-@.5>)F9+[4-YKZA1S_S.!-[ METF1-K3X9*@B"@S9E.0Z%%3;$'-*8LB:,XB^GJ@S@Y MY3&VM)78'1;;@$!%8& 4JG/1T8$3",:A$H#T$JQC\Z%VFZ(?Q9 %E"/&$$F@=@ M,O0A(@69[ 0K#_3-UY1$&S%?[L:3^2S.C-1X=HFS^0DP5\U.6GD0? "F=!Y4 MF4R<.Y[\;?YW5$9Y0."*S3B6[V*8[M9SE@"9L*PJ5R"T6"Q9L$B"P 'VI1-Q MQ5 A1;G65Z:LAF%+D[1R5Q!8;97=WR@,HN-MCHQ!H-'?'H?_LVUT)XP1X&$' MN\SU-& SJ4\%=4T0&+08,TY6"BDJM;X>=MA/8:ON1<'*VZ)@U;$H6(6X*%CU M712LO"X*REWG:4K$&'4]3^(5!I(FMJI=@]%B66?$(@T*%]@?.'94(6@?XR/; MIDJ[)M^ Q=?*P[GX8&DIH'.6;[/-9I5PTR8*@I,V9T;*S3P17DV,I-H'&YM% MG)%%;N@\IIA&,4ZJU(VVJ^?=(E=KW;NVXZ;#=OO '$02#5QR%P^XT, M&M[+*%2&%5?+O-'TB24;FF&NGF'GMA$*T+FE![#9I$83!42+W1E 225&N=K? M0^%Y]HIJX96_ZA-L)"1W_(AXJVGM27&K-B!N6@U"SXT7.4?VZ^4\RN/CG!GA M.,KB1_(>9[CP![89DKM^@+/-M/[DIDT;$$:M!L%G-:L8F:X&EUQY35O#3\7R M:\5:[C[75.Z3UQ@6S?PUE20@1&R^6K+8<%1JO?$P7>,D>;=)8TI2>%+25&YY ML%IL\M"0!,2#S1? @Y*B4NN-A[,UX2LQW?W*V5-V5^20!=L'J-WRT6JYR8E5 M&A O;?X ;LH0E,>4:7_] ;3=)T#/,T#"K;5(':,#FM6X,70A00.9,XA)2"2O MQURQ#,T8^I@2E-T1=%:\#;J>N3ZOQ^=;4J)(/G"1K];I G,;1FUBYV], 0T; M[TTQE$' U&D/?H=*%8'*$ _D7 N6>?T<3QF1[P<$GZ3H#G%%45_S)4M=^B"( MZFE2YTJ%-4^\5:!ZUZ/OK$KUA/SPLJ\AUH"O[T@( I,5U#:/B5$2NF-@7>8WO/-0Q;M M;CB+")%W:Z75R-5UC:YGM%MNGM6D)E&]0@-B[3E^ 0KW5:!:':]JLY?O"W[R M9G2988Y%]],[+ [B]29+Y8PJS,%7S%N#'/\4T:,!V@\2+1$!X=?#)O3CA(I$ M*O05RH-1+=KC>5NZSTY(%N]VMV1)N'RF84:VV3NQL_N6,X\>L:[/ZGHW1S_) MZPP, L3GNH5. 5-4KP#-Y7UF117HBZP$J5IL[VFO;[H4G\3F>?#I'LQ&8W'G4@;(A+"I:#G'2$[+W_]_KO(_GOQ0[<;73'*D[/H MM8R[8S&3SZ/W)*5GT1LJJ")&JN?11\(SMT=>,4Y5-)+IDE-#[8%-Q6?1CR># MGTC4[0+.^Y&*1*H/M^/M>1?&+/59K_?X^'@BY -YE.I>G\0RA9UP8HC)]/9L M_56_^+WCZ8E4\]ZPWQ_T_GCW=A(O M:$JZ3#C=8MHI2[FSU)4;/'OVK)%G'::\,9WMF>Y0%\#N1:':F M\_#>RIB8W/;&:B(OPOW6+6%=MZL[&'9/!R3TELXB][]U;UMK M*H6ABJZG3#K/>NYX;R1MF[3!YB47BL[..ZE1:UO!<#CH]W]VIW^R!S+KI6V; MFKFFU8EZ>U4O%=54F)SM6[MCKPA=&=NB:%*>R-5_1'"&&8\%P)T/\H!MV:9SM36-3^;RH9=09E4?#OYZZC:[F\U<"OOK ME[RRBZDVBL2F/!LG4\KS.KY8S &D]Z\CFQ$]S1M#IKMS0I9Y>#W*C2[WY%%V M^X.B33PI=G]Q5QUU,MV1J7.L$FX!/,0=QKSK[87:CY^HN#RQW=PSMMJ2"T1O M290]7S=>,+YM$S,E4Y^(184R&+54"56V?^WW6Z*ZO0SHV&YJ@/([6&3U/>J& M+=@)O[!AV!H;1IQH?3V;&!G?7ZP8Q(UJD?^C*546VTL$UYK=P%[+E##A]Z0. MVS(S? WLP)^/_;_Q@9/*[ZE";5#:-O1 M?2)*$='0I/UPH,)/<=MW$]W_M+'#1KOE*/O.GK5^L+N/ K]K73V#[Q*G2L1 MHTE[86-(7!Q7G,SKM3V ,4=H*I;2PM3WM=4QXHMG4@-*N\AL6^)QXE=0Q*Q MM[BE<^82-Q?.ED>X^_ 4P;XU'M6A!&DCVG$A1$;X+5U*U>#"/A+[KGF4^'4D M$37_/2/*4,77$-DK8*#R/[9">0]5S-&*'3QIYL2"J%]% ^7_J17R^\@BZC]9 M4,[=^P. GW!(7+A_<(,$R@ANQ4P3HQ2^M\Z)"&]&.&ZJ8 M3"P5!3"B @9:\*P5%GBHHHM_*1*H]%LH..EJD?('/!%UOV(Z)GP3U97=5_?H M?2?\&CA4?]RLMY$ON@>?*5%@!W; 4/UQ$^$&K@CJCS*E]@(*=CY^-%1_W!2X MB2V" 9?",+-V9YZ'QA9614$%QTU[?>S0A"X??@CCYON$Q#Y$0@7'S79# M+-%$']F@%>%CD=#5;W0=4KT"A:+I?J-82M1ZPN+FOJ6*A2J/F]N& MF:))?T=6X\2&SF9L,[&NV0%O$:@1N(DMB#>:'V,12[64.T^]1S*S5^MZ))/@ M;:"A(-0;W(SW" W0'+I($JN=+OYS; 8A7VKAX+=A+7 CP+=%'@R/\V (]P W M$V[DVR(/3H_SX!3N 6XVW,@7VX.1W;Q6=_+1\TK>"X;JCYL--W#%5C_G<*UN ME'Q@F]4*31942D!]:$.2'&:-;48Q4H!BVX:@GN.XIN/=0"!BHV;+=?RPM#76:XH\3?L?0147=P4 MN(X5@KAOI7NYLY B^$BYBH**C)O+^MAA=-9NM:#V]A [A\$3!'&[XD,^")I^ M4LS8*-P<_DP4SY \+P,]4*C6N EHD">"[A/)6VAUP/AM,[MZC>TQE54%#A<9-.'SL$H=_+.T7<%SXFZW0J MN7^53RT0*C=NBAG@B*#X7BSU6A] H"KCYI:UO!"[CLM5O"!B3OT3/>J14+5Q M<\T02]3^>@[JK^=']M>X.:>/':+0F_G[]GJ[GG(V)_YU@\$"X+53K9 _P!EC MZ6:^E,M]/$JE>2Q7=J/> P\4JC[R4MD03PS=LX09FFS"NF*"B-CF?J\$"A^K?A_:F')]ZDU\U<\^T]:_-EP9#\OA)0%]KP(C7,&G'Z MGZ'N"VWL@;XFAA11ALSPE8":T8:7JF'6J(L=U,BRF,OPC((#(%3Z-DQ(KN6( MIO@D)9R_RK0-6P>[H ,@5/$VS#RNY8BF^&5*U=SV?V^4?#2+8IUO2'E/ :@# M;9A?'.2,Y\3JZZ<'-BL>@S;4H,&?N6B#!UZVF%]VB6,W[V0S'! )41X+0GBH M">U88.MGC&##M5E0M3LBRP-R%$+S0YI+02W!39BA[/%NSCM?@@C>F_=P4/'; MD!K7,<1;%)=-.8NON"3!\?\>#"IV&_+@&GYH6K\BXEYE2Q.O;Y2,*77OA_3V M6@1D8< 30/UI0X9\E"9X3R^^?D-ULK *Z.O,Y'_WP<88?(81+ ?UJ0W),T0! MQ#&5_KJ:CR:OUK=T1I6;R'%'5^:5K>P^/,0"%(>:U8YO6X'UJ/'L1:]"T%9Y M;X\61]P/]ST]:5?B2M/?/FNO:NKJA>._C<:*.25&J:L MJ5\C?(R+$*J*FB2KO:\1V^I&_N'/4M: =M5?-KI&]9>B$>'PZ'L6$R MIAF].)_/Y^,C;!-Q&A5&H>T2',?'[Z\N6V*?#H2HK)J6H(ITTDF1U>?%\/'M MI&G'4.1 4WSB(4G&YT##6VG:P=\X$W=>!II:H4W33E/+:RJ;6BK!9Y?1X;28 M=!@M:LLCS< AO3]I7DZ;6^'MITWCEB&H9EWX63BR9Y#\Z<RPANX+!C?*\3ZJX8VA*=0,[A'22+"-JC75JAI,% MK^/X&GMRV#,QZ2EJMFH9XW#.W9<,H=?!-*QYTN!A"%57[>;#I.U 4RUJT'%' MUF*B-L#F"9[CLA$V6JD@P5^"_SFR9$NAQT=QYR^\'5!+( @F2E]L^?5KI(2P M5"O:!IXB1'2^?8U8=&3%G4$=QWYQ%^S1_T6CI"I312J0%K4.25T8T (92:-# M4BNS#X]R>3C\CMXPR7CQZ7:X!*52>]/M(] M77VD8+' OROHH(0QR60CB$H-56BHPLZ?N3 J^4R7":37 =NW@>W.*"J!/^W MJHK0>^P*BDG7 )4Y 5&7'_E'U]DX,.'1.C 2CZV^8%#S,?'(?*L#Q&3/UH%3 M1EJN75C).9(6 N]HTIB8UEBA7R-=T'J!\)QND;8\@"9U.B1-;2"H!\Z# R# MD+O,UB7YU>LGR::N".,"4365LI?RJ(!&2PT<#>R;+$E496,#OT+#NCT 6*)C M]B.KB;ZH:F@#M)4H#\,[:VG3SQ&B M> BLJ%4&N('$_-X2@>0+$9K %;B1PS M8PE%% ^PBWC!D\)@@EG1=%J@RRZ8;"X& @B;8 M]YHT'X*>BWG")C4PIXKY& MO___*Z42;MR=/)2K2?-40+1A6&7!HL=3%CQ(TW=S MW4"5"SIY;V;)"A#@/71%NJJ1=NTP*_>JK)E7M%!AQK_F."GLJ0]M&_? M"_>5!,2,=$469" 2G&O\7-+.+[C_D4;/# S'8@'IPS@P$53-N@QV[@6( V'C#O51 %0EL MWXE"%Z)PA< :?1C'--J=PP.1*=C?O&RQ+XO4!$LSYLUO#1G,TA@&U8>T3%5M M(*OOH7U?+K-XPP![[P-2F!.H&SKZ D4G;O6"]J,X](>_^-\CW0OT!X+1D]4" MX2*0U^K'[[_TI2Y-6Z'1:Z'',BQ_]C"4):N/:0?W=R3PHJ,90$S4TO0".5$$ M\9DD(#,Q-466#HG[LJ-9X.V\]_ST/>8R45-^@TP)GD:.__L?/L,=.FRY__J( MBP>H6\B7!T1W)>-OYB1/'4V15LB@#LD$*C3E#@F.UJB@R#UX)%),OB/'M_5: MNU(FK7:Q76D==0P6];46. M3%U0F;_ +#G/Y5CR'XV6-=%&)X^5ET=Q4J>85BS>,C?GU:O!Z97T70*K_-'D MT8\OM$^T+K'Z=.(&J&@;LB4#TLI([ LJ>*ZB:&$K/I], M_>*C? :3,XI]X*-#*O?Z%A:=W<,JFN&1?; P,4#7,E00(BQPW1$O#D#E[0!#NS_0O:]G%UDS"G>M3.-D? M=8YG]5IU]>H4#YNT)YOH!2PLIH:KE7O21_7\_;=,\WD#,T 87DA9W#H[.9$U M&+\OMFS*;.27- ,LE2T)+51E9_)QD3 X1QB.R]BKC 3P$$@2C@QC0@H13&+J M5,1\32(R2,TR"?@4&"C&_CN&LQV;L3!_@Y>* LA%MB;*1=AW79 D[_O:A/@B MS4D *6J*(N@F2,O[Y.031Y;A(7BEAB6+@N(1#0&IEW,<6=),&)M,_AT,/H&N M-4V86V#"Y8 )UU1Q:B,L*RXYRUPE35I@T1WQZ=DJ7;T:/6$3C@I7-S&7M:AN M:*]H5T%/M0*=X+FI(@S!QRVR.HTUAO3J0;,U]I)82/ M3WSOBR\1.4[PD&I4%4TS?@G)E>!CPVAK0S5<;O7&Z>7KB?@LU3<7 L^ACAPC MJP^:\;Q 9@=S25HRC!EFMPWC&F(1" $6E76XTT%/U,]K#W33',W@![8>EH;N M6[:!/95ET 209JFZO\'@X@/()F'ZB%VU@M8H.D^\-8(O%!R;]9P2J[AH$\J&E18 M;"J)S.C^V^A[-9_+;\!4_/@BQWD^N\ T]A?6L2\U&)_7?4U=FE;4RZ5&O5SK MWIELE$OPF666S2)9LC_5*L0A(.";!3RC%83@Y?!1,)JRQTA8&LC OD#GA$ODV26*E99&%UY\Z0+3 @K)C8JINEF^&^^.R" MGBH7I]GT$[^1Q8*.IBE44-EV5+^7#B7)L8'QLLP1. MR4:CVUT4UU;SO5RN=O54S'T\KEW%4!?3M7F#!5Q1T8?L7<_*IZ1H8J^SOYKY M.FW_&/!F#3@1;L UT[2I\:X9OZ7NRY7<=>?-V,BRW*IF/$?=9S#F)(VF]L35 MC-EM&S#F+18OYNQUFQ$\S%S3&,G)+J@!^8D>MDL(AS1;^D1Y@9BVG%U\TD6@ M^0+F>WM$WREPIK(+"IS+%RO;>-[3V7LD]HF(V]27KI6&>CB/][\#[G'3'/*9 MCW%H"*PZTQH/.IJR9RY?"U[.W_+2P29X]N-+IC_$<-W=,\,T2CV'!$-OV)?A MR71\AJ_*AMGF(LUL9'' MW[ZWRR_?U,9X6%MCWEI^",Z?'LP0'SEF#0_<<07S!PB=E6.Z!*N';.,\?G&. M#A%&/1%4B;TU)N="B'LP9(5]5:O;\WN!S?I0/JQ\KYKMCE)GD&Y8\_?)1(6V M;S(#ND[DO;+J Z0[!WMNMZ:N57S.]K25GAFJ7KBS<%_BQY5F7JCCTV?U@Z!WGMX*%<0?S"(0K=<&4A!=WL%X)QC.UR.5E:45M;\['_I#V-SOB M/R60?W V*VU\-INTF3ME^OCV]-9(%:O<0[&1_-@H67QJ=^GDYI^U#H@N&.15 M4&Q*_N)B>+Z2Z'@0L[]DI^0''.$_Y?3RFYVBEJDS>?J/BMI5V+3K4_ MOC7NLDI%/:>OYXD?"NH6WA>P=-)JSF557G[F?L4-9X8HFZQ)%[?N+\[4+$C6 MO/84]ZR)K-%?/!]+*FLRDX MF ZBB@<04'.\X!C_T\:6]X)2=R7 G7A(/'Q;;%=/F%-& M2\DA)7P),ENJC,;)_D7R7-GD$J1EV'1^;W0H74P9"6[5Q<>-:6SKFQ1A3'>7 M#%+<[3HSY'=WV)B7Y[86]F% 4X6*%@QH56-K@#9$2M@*D+H;&/%J ^<,L7,S M$(NZ$)DR1NQ#&7"C(MJ"5K JJB-MC!)'=EPJ-=W?P,E]),"33 MV;LHA:] NFX@N2?L.Q]=5^ ?_[&?-0:"IV0KH_9$(,Z)^05[GNZKHY.$D;#* MZU1]UE^#7T35FFOO/W-Y=YN8MG51D&\Y,'2YT'>1T.8N"OH5=QF$*0"Y.P0@ M+S;NVP!<#JLL@)Z7^L)U6/]&8#X1LL\]PP+H^7N6@COOO9NHYM ;5'B.=BB, M.J!19S3[469","(9ZZ+T*_\WTGOGN :I!N%C'!\C%3R/CYO@-2(0;S,F*6/L M*.-AL=V=8L^@+#.)3<\I_=HR"-\CCVF*K$ZN8Y].>[*ZN\,DEHAQR4G,6K(- M _/Z4(6XDL8=A&I[$ M@LB[Y.4J\(T_W <#-FVP6Z#,5DU,ZC#X@_ 'GFN&F]) %.HF@9:VN\,*?Z"1 M/7F?U&$\]%N68# RO@'# HAWP?4T"&<=)FBE-U#NX,, )%4+:.<>9?Z43Z M@.,XXJ=WBJ'.J'!!0,"ZN[,G PFE/D2N0/Y$(#7UE9H6VLT,(;,M76!L\XBE M]9S4%SX[S\L9UT&W'-D'FIHD) M8@N& MQ_N!4Q@T14/N.*5!AQ(-+P&S;)-5#/ 1]&&6)8%1ZY9S)7.28_,,SPRT*ROP ME]0OX3OHP9=ATCQ6($3./.A4XFGMYTC[YB(X-: M&@2J:%:H=QP#IMUYPH@"C8F5K@4(8MD]?TR\X$\$6[$QIY@:4;P"MS>?OC4GK"_E]A?7N)F M@T 8L*+9;R5B],@]#8W*&>*ZWZ4ZDPV,G1<;T@.\[P\=*/,BZ*5@D(V#B8JK M@ZX-IHTX9^9]4=-1KM-A9%#7*0A8_N_+'03- M>W=UWB4L\>,G.^8%X8#.Y7X&S^6I]_RQ?5N+=Q8(Q/G1)VN02"1R',])_",= M\5R4C_6MP2;Y00\\X4!8Z[ZG36V-_HG<7L]4*5B"['QTPMFYFLDDU@Y>"[UH MU\=*)1:8YUQHRY>^ @>-%E=-9M6W=2-,;,$($Y_6"#?.[=0(W0+->Z:W6N'. MTE8ST7>+7]NRIPV:2VJM;6 ;MI2-\5'2 "M;5 ,=@(P$D=V_5Q8L@; +=:-N MV0:;X3J64P1RFTG8#$-J(FF %I?](3'&:I&;MX?#A,Q2P+T!&'[CS\P22^@Y M%3],XR7)3=LG,/#G:)V&DGN__/8OF-W&\L,*RYF)/\N9VUC.W/ /0BR]'FWM MG_& >*Y5.ZT7V[?-RK($ZE/\JLC6;D;S_\2(L[4(YAC#23)7W;]W$+8I2;*5 M,6$.1W)R>_=G. !/AQ(3R*)X"I=YHP[M"TK7*VNR:J[; '-\6\6%) 9/L*V^ M9H CW7Q]9MNWI2U,$F=N/ULW8PR?VP XNNJOD43D@]:\T'S?"74;3:&-OS@U M&S]LBZ%5?IIXP5&07YFDF=2:75R^+,I9N[21!( GX\+'[EM8&ULJ"^A(W(R3 MEJ ^4?H*?ZVQH&Q'SV*]ZV!W$9I>\ M.F2Q?O1\7+]5K,;PK7AS73E[-6M&RJAI4JEUECGAOYW(E8NGW.N(?Q[R#^?U MM*8V'U(50WK.-D^*FLQ7GKN7#X/OR>^Y5N?\JCQXNN7-_C!W??[0>TC>E>DW MH5FYNRM=/(WYRLUSO'%Y)?;?>@_Q.RLQ$D_?\MF4UJKTF 5RH7%>,E M>?;0&PG9+Z_E^+=6N65V]?VE>W&5.MGO=\G+5N>EE\5N^_%COG MIU+CI=2N&4F^5N>&NL%U:U*^:S>^O5[43EM?AC<7;W73/,\.$]73Z[?[-/>E MF\V?W*:MM_1M.Z6JY96BW0_2#;Y_/X[GN^G.=>7V2S)S.CC[ MPI>?STRYDKJ[JK;3?+)J7F73U7@UG\W?=)-%OJ.>V=I7QTS^'U!+ P04 M" "N@$M5S%8;YLH6 !47@ %@ '1M,C(R.# Q,&0Q7V5X,3 M,2YH=&WM M7&MO&T>R_4Z _Z%7-QO( /5T[&PLK0"*HF)B)5*7I&P8%_=#8A MFO?7WU/5CYFA*,=.+,?:;&"$U'"FN[J>IZJKY_3U^/KJK-DX?=UM7^!3T'^G MX][XJGMV>F ^\>N!_?GT?'#Q3HS&[ZZZ_]R9)G'^2AP=+G,QU@N5B;Y:B6&R MD''+7&B)D4KU= ;?;%\/NS[W1 MN#OL7HC;_D5W*,:ONV+4[=P.>^->=R3:G;$87(JCGYX_;XDV_K[NXK8+L4OW MV>'KM[N)]NWB[0<3R%2! #-WN_/?MSW,W&Q<#H:BUW_3'8TQ/";L7[T3[?Z% MN&Z_LX\;@L5H<'4!#@W;_=%E=TA4X\GV:-3[N8_OO3Z3WSX?=?N=+M%MEC=L MCWN#/OU-/P^[H_95E[X.N[BT;=G-!J\;0^.IFU[?/GW=_A=N'7;;HT&_?0X: M1QAX=(E[B>68'>NXAN0Z@YLNTS^Z/1^-VT3+>,!3= ;7-^W^.WQOC_%KYW6= M0L,B7#.,V?^B.OK8ZABH.%#I^,+=: ?Y\?#O)^+35UCE8Z2F\%8WJ8X#O921:"^2@L:Q MR_[NQ?&+UN'A(5SNQ8/3/_^[K_0\<[9=4+ZJM;B7">B'?Q:Z$SG.HE% M)TF722KI>\O2)YN-"Q7)E4P5%,;_+';SN7)N$'I_+=^KE+3=.<&66*;)0F>@ M/T_$4J[I@YYA+21V]Y,TGX]RF3(9;T!@D=+BKJXZ+2&%GS72"PTA-1N1EA,= MZ7P-0A9+&:];&$SH/!.IFNF,ED2BS," C'[)BB!069:DF= Q_M$-67YZ.8"C MK?!Z[TZF6A)[LH6,HKT -E$1#]U^MK':&[E6JK;:9@,3\M):O,JE5^*L6-!J M+_6=$J^+."0BQRNL=FVNC>=)DR3@@+DW6@LDC?K-4! UN[D_50H(51;R4.L0'22*?:ZA8 MDJL6<0D\GQ:16"0QU -DTUIN8^*_@*ARQ8;27D#_ @GR8KX!C%UD/$V0Q"&K M4M9LA"H+4CW!DQ,5):N-J-@&.="*!1B1F7$L&9;4B8)ZAU@=I#U7P7MBQ4I# M'?)4QMG4J)!>+%2H05:T%O).ZDA.(B6F6!@K )DUZ$M74$.BA^C4,1&T9KH- M>\ GYK$, L==^M$P<0'%G4*110[+8Q6F3RP-2H9Y::15JO,<(H@3^$E%3*21 MTI#D 9+SN56(Y YFQIQAOMKE[C^9*%<%74<;TOPR'][S[_N5 -_-(;O2G"8R M8L:R ZEJ"Y2)I6]U,B3IX/MJKB%;(VEH)ZQQP6I,;D-#L36-6610BRPCOS+1 M\0,.#NX)O@?N$,]7;=\1.ZZ9O:.3%(BH2Q7;G(1^Q6O6HGT8%AE@G(A IT&Q MR')ZPMDVW0:_K>]T6,B(C#.(BE#',Y";D[*10V3/2&I)=R?3*100#BB$G2"6 MX9M:+*.$])@=)Y$UOUZ V@1?6D@ MYXX-FHS0EV)IBK_(TM?KX4;2Z9P,/8UH'ZI-FPP4D)^\@2 NOOM9%;]7[ M)^X[GE<9\44_,/A%*E=ALHJ;C:'ZM0!W,YIL7]2-L\I$9Z$AGHP%/;O%X>/1 M)'4(QKD"09Z@)8HE9)::V/[-,\,XLE&L$Y2F4#-0%2B]SCCSRWC@G)CB%*FR) M>;)2=P;$P%71:A?R@UX PUCL@1%"^WS&&00\#6 ,O,4&G!#X? CT-!L?03W[ M8D"*+F,W)0:J".<^:G$6!)](@JP R2 MHBAIH42^G ).?Y]F9-Z953),&#N/\@"5$6&8 &%[I@R\GFH.S"#$/ ?:"T_O MOWG8>/$HJM9)8K@[PN5/J^3TT?Q^5SY[#%Z=WIX-EJ1M,FHV2L:='MR>D<\F MES=1\+EJ6Y2TT219.G5EUVF89_;1/[ND%*2YYW+DH 01F9.(,7)$XS MHC$B@_LK5E_B-P5KXI_5ENE69 MY)K69;YEUG(,*0S3[XS[]&NB] *&3!6J;0O)@31([IRK$R8JTF5"55=;QL*8 M21HZD\1-YAO7\7C0DGGE-5K1OKBTZB[O$LW5+ 9C85),\I:S#D+1N4D6>/92 MRM62'BS?L)A5P:,CB3+)"WAD$]$$"G\,K]E M\+-3XH^_[>TA4U)1^ KKGZD3W(]\ 3+ L&)OSVU_7/3>N#G-2'MYLL0MQ\O< MC;UG-FQ>B9=TS6X"N6OG"!OOQ1$FSY)(AR#@ICX>4X:5QI-LR0L]/<"<6Z:? M0 _?[YGX_PIR)IJK)+W<0A&1^;E35AAS0)PQS/@RXO0S?G7 -OFR@ U(;"QL?IG*P*%S)Y43T06""S@8;R)V*G?X M1TH0ZB.+Q:%@@!ZV6T9OVKA-9[@-YM M"SGB.0UWC&$#L"Q!C,T*NN9G57<:"%MDU @ )[TO;C_"-9#>;' $]+# YO\V M[_?5)N!. !V'1;= NN!9:]O.64#1.HJL@5/X%JY(,2U24]$*?'G%,!M!V*=D M84T $ZZD45D0)ATIH/C0U#GI1]I'J>X/T,/5#8*-/.[)63'7'EX^2NVA2]C) M; =>J*F$FE8+7(1,**TV(L@F7FZF@-WW6]VY&H:\>JI MR>!K5SDNI8Z*5'&9C0R!B[6:"H6N$FD\J+W/UW!]IT-ML\'Z*RHCUAV',UM; MQI\2]-]]L;6.;_>,;:Y1\PMUEX#,;FC45?">5<74,8 U;I.^I M2M*9C/7_F08;_#TW?M)5NMUN0Z87.I(I-6/P1H(-E9DE1_O @TD3H# 7.^A6 M^9[?" =)EEVH)OABI#BVAWV/3*D,O/4XB!O@3X3)#_QBWDG&:+ M(J6;Q>X]ZK@DH&7T3%1CB-LS!KPCU&>*23)E^BA6($(C])=G%V_M'V&4=A#,AK:IWQ,CB XP3'V@,3.JLZ\D;#SD MS4""PC.W=09!V'V%)'7^.TR"PNSZ*^I9 3^LS\JD;=BQSB@E[PV": 6N /7D M7,C7P<5?R%0R\;*D#!)[:>L3G]B7L*' M.FQR&J*2(W>,@UKZ5/+]<\5.5C, M.ZS6EJIJ7<*\NIE1P*?$6A(B<+K.<=Z6@"Q#7-ADFW]R6L2!Z!^/$HC>DNFF MM=8<]GNFU$N\M7N)J:D-S0I)Y;2$=Z",Q#,@=ZX539.T6LYBKU!U/ P2;*VL M=$*ESPEU-D]B&L0ZII;9:2WO< [KGC(IIX%$<)IR;A$J0B:9U25 DZE3IVO?&[U':;V62FUKZ@,WNN&]3W\&/,.YWF MA?>MEBVB;'$#S,QHPWNQS%T9M@1XJ:+"?NJ[>\V!!;[':K8MG]*":"-5<200@1&91K5_*NUFHD#"F& M[CDH!T/8RV3"[B[KP&2&&_V4BIY7;\,F5WB#CVNLCA9LSN39FY.8TKJ,Z:>9NF]3D2O%.VKI\3 M?]](Z>7B@&QY7.B)>$/M M8_CYZ[1+_+X3K^;D<+U3XG +,=P1466"6_Z)&*^76&4[A0H$)Z*/),BPJ)_0 MPH]K#1/N*?KE+]#2\:>_F^#H\(_&N+X)21N=[P[2@B!&,1NG%% M97QQ3B?#9.[.0L*]MVRO/*T& -*MT5A^N\# M:N^L'LZEN4WS'OY82(W(D6#$F"$O56XUE4U5>F<]'^]QA&'*VV#NS&58I6OB MX"C'-Q#F*9N HJD,N$+J!XL+:M9$N,ARKL#&>;3VIU_\25 >S)^]M=442P;A M;?G!#22=*_\X>+EU(ZVS8K8Q?XL,4=U%U06"[=T7B+B^=;+&10K+OLIUV97V\$M M/:WH7JEQ_OQQ=:NTLF=N3SUQ\6(-1#F(UI-^E/?Z"W/:34;-!N1;BGC]A5<>IH _^@/GQ+N4+]# M:HZXU'HC7O?,JURZ8O2Z?75%+TCI#/JC\?"V>\'O'^GV+P?#CGDS2KO3&0PO M^&4D;WOCU_PZDJOVVY%[+$'O,,'P MEU<]\TX8W$5OG'G3&_4P:;-A7ZCR1*7TAT^]CJ@U:$N:!1]!+=062%=JNKK: M&VQ"E.;=*'Y'D8D316SS)R[^V>2DMI_''J7%?<[6^U5_;ID 9G:7^,BA\ZR4 M5.2^U=G-JDTW^7JJ$]40Y__40T=TP8J=462C^8#P?=0 M5G67H-R'<*<:ZKL*K?3#@5R;ZH3Z,6$OIJ:9"7!ST!1 M-K7U?;=%SDP'-)I)*N1N8::[T1SL!&-EGB7D^)ZH3?W 9G#ZAP_BM\'6D NN M'[&O-C>UVAN%+730"UULV*5^NG72HQ=?2E2^JVJK"X3VEVU7Y&\J+]HIP[4S W)N)N6L-/_Z\E-- M=+:6:'(3*_Q=7*0-!.G<4B17/I.@]_4\,SZ!0J]MIR1]N2=K]LQ"D>[111D<52 M<\G94G9ZT#O[WV]QK9]U,NKY?XI^7/1[_E5;6G,_EO<7R36;L M=+EUT+W,T!52R!&NE4Q-20X^GMK#G2-]3/?V3;R;TNM"[8V1G0'1T/_GSO'. MYRY[Y^QZT*>WQKX3Y[V!>9'KJ,>O,.T,AC<#\SK3C5='_KD$>\%\2S25(_XN MDC9>^OF"=&,KE9^MU>XUHACP?/UJ^V@?#Q"?\_93.]L//V*Z@^Q O-51I.5" M7 ?_4HJQ]#3SP^0% M48X=6UXKNRE72(' 3$^_/MW3@\/7DXOSHW;K\'6O>XI/0?\=3OJ3\][1X8[] MQ*\[[N?#X^'I6S&>O#WO_;PQR]+BE=C;711BHN?*B(&Z$Z-L+M..O= 18Y7K MV08>Q*.7G_K<@9C+_%JGKP3=NGL@"O6^V)*)OL:E7%_?%!M'A\='O?JH+ M#+B]?[AS#+(O'V/"WTI3Z-ERX^C[__K'_O.?#AY[&JQL\KH_%I>CX45_/!Z. MWHK!<-(3F]\G\>]E=D!_?)_SUV?B=7?<;N&*..[U!F+4^Z4_GO1&O5-Q-3CM MC<3D=4^,>R=7H_ZDWQN+[LE$#,_$WD_/GW=$%W]?]'#;J=BD^]SPS=O]1-MN M\>Z#"62J0("=NWORWU=]S-QNG0U'HC_XM3>>8'A,.#A_*[J#4W'1?>L>MP2+ M\?#\%!P:=0?CL]Z(J,:3W?&X_\L W_L#)K][/.X-3GI$MUW>J#OI#P?T-_T\ MZHV[YSWZ.NKATKIEMUN\;@R-IR[[ _?T1?>?N'74ZXZ'@^XQ:!QCX/$9[B66 M8W:LXP*2.QE>]IC^\=7Q>-(E6B9#GN)D>''9';S%]^X$OYZ\;E)H681KEC'; M7U1''UL=(Y46*F=M7%'$1U[&!+( :WOGYY?=T]/^X)>?-W8W^._Q9??$_^UF MG69YK/*M*$L2N3 *9+MO!^).Q\4-4;3[]PWV;X>3D7_L5N6%CF3B%SO-BB*; M;S@W>#@Y]3>Z07[<_?N!^/@5UOF8J!F\U66NTT@O9"*Z\ZS$.$US^F[OQQ>= MW=U=.-[3!XEX_BE$;!R=RD+%0AJ1S<0P*K*IRMUL/W;$_N[^/D^&_XTL=W:8 M\2R#)Z">SENZBSJ-%0VZN_U"IQM'%QGIKEJ*8YV);O1[J8TN=):*DRQ?9+FD M[QU'GVRW3E4B[V2NH#SA9[%9W"CO$F$#%_*=RDGSO4/LB$6>S;4!_44F%G)) M'_0,:R0Q_>1&YK%,1:"FG]XJ4\Q!J1'GYR<=(468.M%S#7FU6XF64YWH8@EJ MY@N9+CL846@\DJMK;6@DDJH!%PS]8LHH4L9DN1$ZQ3^ZP12'9T-XWAK#MVYE MKB7QR,QEDFQ%,)*:C.CVHY4E7\JE4HTEMUN8D-?7X:4N@E:;"R2.FLV@$#6[OS]5<@A5ENI ZQ@>)H[C1T+.L4!WB M$G@^*Q,QSU)(!6336JY2XK\8%S ;MIGN'$H829"7\@U@[-SP-%&6QJQ/IMV* ME8ER/<634Y5D=RMAL@MRH!I6Y#R.(\.1.E70\1BK@[1O5/2.6'&GH0Y%+E,S MLWJDYW,5:Y"5+(6\E3J1TT2)&1;&"D 6#OKR.^@BT4-TZI0(6C+=ECW@$_-8 M1I'G+OUHF3B']LZ@S:* ^;$>TR>6!B7#O#327:Z+ B)(,SA.14RDD4B_\=>= M+FZ<0F2WL#7F#//5+7?[R\>+KP?&]E:$^F4^0D38#BL![KN!""NKFLJ$^0M6 M-I4&.L5*X%0S)B'A^]V-AHBMP*&D,,HY:S-Y#PW]UC1F:: =QI![F>KT 6=7 ME)#W$JX1S]==@"=VTK!^3R?I$5&7*S8]"35+EZQ,V[ OLL,T$Y'.HW)N"GK" MFSC=!A^N;W503E_@I:O?\H6MUW\8>QK@?[6;OEXY*7=Q3E95!?YZG7ZOUC MNI"OP.7G=49\T0\,?IK+NSB[2]NMD?J]!'<-3;8MFL999Z*WT!A/IH*>7>/W M\6B6>S3C78$@3] 1Y0(RR^UL]M$07CB4M%N;2D8W!&TJ=^+I%([,AD-Q(9V-Q_YI@0G%DLEXC-,R@9J(N47A0<@.2]<0YLC(I5 MW!$WV1TP"F,9N"I:[5R^UW- &0=!,$+LGC><6<#3 ,W 6ZR@"H'/A[!/N_4! M\+.-QZ#H0(EN2@Q4$\Y]\.(M"#Z1!%G# Y#9K(2PU+TU&T'DP AGWC5O8S@Q M4Z3/%3S)+8YPE)@JVL2E"@*FR(_0DA(G*.) *AV'0B18;\J$V-9A5WI/AL 1 MK"Y/TY9_>!2/V5TL$L!,XB:K[*631]UQ-&!D$(ND)Z%L,YV#MS8)H5M(1("W M;/DDAB@S'/^C,B?=U-;I>G6&$-U]A.%)U*QT%.EJD-F'XTT2>(:8S.&8J7X& ML4N*HJ2%$GET#E3]?6[(O(U3,DR8>H_R )4)89@(8?M:690]TQR808A]#K27 M@=Z_>-AX\2BJ=I(A PQ>'5X=31XMF";+0"B[F2. MM!#/;E:Q]8V[5H^I#+S=TT0TF8@UB^_VMG=W"?4*]]PJ\O>7JQ6+2WJX$;+; MK1Z%:'_OG8858[:"LFZ;)6L2$178K-%G1GFC#6NPN$$;4UJ?)(G*6W("BT1& MBEW$:D'"W7#I;ZA3U6X9A.X$+%6(M@C1(2F-DLP0ET$!3QI\DT^)%B4P?T0I M!521G%QSVO[EL,%=6EJ1T(UTGTLR*'(J6B/DM"AS.#):=RFJXH4+"L!&9H&H4!K&$W0)J^?\DD#-HE#SJHSX M?)?KB'O.6R>X)?!\K"(R"&U].13F/3B27BLHUGP.H:]).L>]DR8P//;V]:!9 MU.QF;&.9(^T%O$*G@2P-!;][@2TNP05>6E0RJTI*AZI"5M>-8 MA137AJ0&^(8MU,EOMVA@>BR5<\Y:Z9/+>#:19^6E2O6, (*R,O$&+TB<=D1K M1!;WUZR^PF\*UL*9 M>Y/$3?8;E_-XT(IYU35:T;8X<^HN;S/-12T&8W%63HN.MPX&]399X-DK*=[!\RV)6A8!R+",^D%HQ1JJKK(7X[5:=:TYY.)(LLKR"0R$10:0(R_R6P<]& MA3_^MK6%3$DE\2NL_UH=X'[D"Y !ACT0OY)G?"7VQ=:6WQHY[?_J9[=C;A79 M C?O+PH_RY;=TGDE7M(UMTWDKQTC@+P3>R##9(F.06N5]&4<*,7QT*3A\+"HYX2P$AO]T*=5L+!;NAFA6SX_N#"$"^ W^0:;.] M-R%>Y9^L!R!0I5.;?;M=C1IL=/�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